Lentiviral Vector/Transgene/Biomarker Protein Biodistribution Analysis

Lentiviral vectors can confer high levels of gene transfer and transgene expression in a variety of cell types. However, the biodistribution and toxicity after intravenous administration have not been reported. RNA ISH and IHC allow analysis of vector DNA, transgene mRNA, and biomarker protein, respectively, while preserving the cellular relationship and tissue architecture. Researchers have found that combining or multiplexing both technologies provides unique information. Lentiviral Vector/transgene/Biomarker Protein Biodistribution Analysis from Creative Bioarray combines RNA in situ hybridization (RNA ISH) and Immunohistochemistry (IHC) can help validate and accelerate your gene therapy development.

RNA ISH and Immunohistochemistry (IHC) combination presents several significant advantages when used in lentiviral vector gene therapy, including the following:

• High-resolution Visualization: RNA ISH allows for the direct observation and localization of specific lentiviral vector, transgene, or biomarker RNAs within the spatial context of cells or tissues at high resolution.
• Quantitative Analysis: RNA ISH and IHC combination permits a quantitative analysis of the lentiviral transduction efficiency, transgene expression, and biomarker RNA biodistribution in targeted cells or tissues.
• Co-expression Study: The integration of these two methods provides a comprehensive analysis of the co-expression of the transgene and a particular cellular marker, providing insights into the molecular and cellular effects of the gene therapy.
• Compatibility with Archival Samples: The techniques can be performed on well-preserved, formalin-fixed, and paraffin-embedded tissue sections, making them compatible with the analysis of archival samples.
• Single-cell Studies: RNA ISH offers single-cell level insights which could provide information for the better understanding of cellular responses towards lentivirus-driven gene therapies.

Therefore, the combination of RNA ISH and IHC stands as a powerful tool for the evaluation of the safety, efficacy, and mechanisms of lentiviral vector-based gene therapy. Another advantage of the techniques is that they are broadly applicable to investigate the distribution and behavior of other viral vectors and genetically engineered cells in gene and cell therapies.

Features of Lentiviral Vector/transgene/Biomarker Protein Biodistribution Analysis (ISH + IHC method)

(1) Detection of single-copy DNA vectors
(2) Codon-optimized transgene analysis
(3) Biomarker protein analysis
(4) Custom probes designed within 1-2 weeks
(5) Fastest turnaround time
(6) Experienced scientists for accurate data analysis
(7) Standard and customized experiment plan

Benefits of Lentiviral Vector/transgene/Biomarker Protein Biodistribution Analysis (ISH + IHC method)

(1) Simultaneously visualize in vivo delivery of vector DNA and therapeutic transgene mRNA
(2) Identify cell tropism of Lentiviral vector by multiplexing with specific biomarker protein
(3) Distinguish transgene from endogenous sequences, at the single nucleotide level
(4) Quantify Lentiviruses + cell number and track persistence over time

Creative Bioarray offers Lentiviral Vector/transgene/Biomarker Protein Biodistribution Analysis for you as follows:

• Probe design
• Probe synthesis
• ISH + IHC staining
• Imaging
• Data analysis

Quotation and ordering

Our customer service representatives are available 24hr a day! We thank you for considering Creative Bioarray as your Lentiviral Vector/transgene/Biomarker Protein Biodistribution Analysis partner.

References

1. Food and Drug Administration, 1991, Points to consider in human somatic cell therapy and gene therapy
2. Bosse, Roland, et al. "Good manufacturing practice production of human stem cells for somatic cell and gene therapy." Stem cells 15.S2 (1997): 275-280.
3. Pilaro, Anne M., and Mercedes A. Serabian. "Preclinical development strategies for novel gene therapeutic products." Toxicologic pathology 27.1 (1999): 4-7.
4. Verdier, F., and J. Descotes. "Preclinical safety evaluation of human gene therapy products." Toxicological sciences: an official journal of the Society of Toxicology 47.1 (1999): 9-15.